BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 27090170)

  • 1. FDG-PET imaging in hematological malignancies.
    Valls L; Badve C; Avril S; Herrmann K; Faulhaber P; O'Donnell J; Avril N
    Blood Rev; 2016 Jul; 30(4):317-31. PubMed ID: 27090170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT: Clinical role in lymphomas.
    Papathanasiou N
    Hell J Nucl Med; 2023; 26 Suppl():36-37. PubMed ID: 37658560
    [No Abstract]   [Full Text] [Related]  

  • 3. [Importance of PET/CT in lymphoma diagnostics].
    Afshar-Oromieh A; Kratochwil C; Haberkorn U; Giesel FL
    Radiologe; 2012 Apr; 52(4):338-46. PubMed ID: 22526115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET/CT in lymphoma.
    Juweid ME
    Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Malignant lymphoma].
    Okamoto R
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2532-6. PubMed ID: 20009452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone involvement in patients with lymphoma: the role of FDG-PET/CT.
    Schaefer NG; Strobel K; Taverna C; Hany TF
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):60-7. PubMed ID: 17021808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI.
    Chavdarova LI; Tzonevska AD; Piperkova EN
    Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Update on the use of FDG-PET/CT in malignant lymphoma].
    Terauchi T
    Rinsho Ketsueki; 2016; 57(10):2008-2012. PubMed ID: 27795508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
    Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
    Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.
    Ferrari C; Minoia C; Asabella AN; Nicoletti A; Altini C; Antonica F; Ficco M; Guarini A; Maggialetti N; Rubini G
    Hell J Nucl Med; 2014; 17 Suppl 1():40-9. PubMed ID: 24392468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
    Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging.
    Moulin-Romsee G; Hindié E; Cuenca X; Brice P; Decaudin D; Bénamor M; Brière J; Anitei M; Filmont JE; Sibon D; de Kerviler E; Moretti JL
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1095-105. PubMed ID: 20204358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes.
    Rayamajhi SJ; Mittal BR; Maturu VN; Agarwal R; Bal A; Dey P; Shukla J; Gupta D
    Ann Nucl Med; 2016 Apr; 30(3):207-16. PubMed ID: 26661845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of
    Ayubcha C; Hosoya H; Seraj SM; Zadeh MZ; Werner T; Alavi A
    Hell J Nucl Med; 2019; 22(1):4-5. PubMed ID: 30843002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.